Omega-3 Fatty Acids: study protocols
186 study groups say how much Omega-3 Fatty Acids participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
4,566 products in our catalogue print how much Omega-3 Fatty Acids a serving holds.
Most common: 500 mcg to 1 mg, 18% of 4,566 products.
| Dose per serving | Products |
|---|---|
| 500 mcg or less | 11 |
| 500 mcg to 1 mg | 842 |
| 1 mg to 2.5 mg | 128 |
| 2.5 mg to 5 mg | 392 |
| 5 mg to 10 mg | 13 |
| 10 mg to 25 mg | 49 |
| 25 mg to 50 mg | 162 |
| 50 mg to 100 mg | 331 |
| 100 mg to 250 mg | 788 |
| 250 mg to 500 mg | 579 |
| 500 mg to 1 g | 701 |
| 1 g to 2.5 g | 503 |
| over 2.5 g | 67 |
Dose per serving from research
186 study groups in 124 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 2.5 g to 5 g, 35% of 186 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg or less | 4 |
| 250 mg to 500 mg | 12 |
| 500 mg to 1 g | 49 |
| 1 g to 2.5 g | 55 |
| 2.5 g to 5 g | 65 |
| over 5 g | 1 |
Commonly used together
47 of 186 study groups took Omega-3 Fatty Acids with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Docosahexaenoic Acid | 21 |
| Fish Oil | 11 |
| Vitamin D | 8 |
| Lutein | 3 |
| Vitamin E | 3 |
| Zeaxanthin | 3 |
186 study groups
| Study | |||
|---|---|---|---|
| Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial 2024 · Marine n-3 fatty acids · Men aged 50 years or older and women aged 55 years or older, recruited from the United States; prevention population without the trial's excluded serious illnesses | 1 g | 1936 days | 12,933 |
| Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis 2007 · EPA group · Japanese hypercholesterolaemic patients with total cholesterol of 6.5 mmol/L or greater | 1.8 g | 5 years | 9,326 |
| Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial 2025 · icosapent ethyl group · Adults aged 45 years or older with cardiovascular disease, or aged 50 years or older with diabetes and at least one cardiovascular risk factor; statin-treated with elevated triglycerides and high cardiovascular risk | 4 g | — | 4,089 |
| Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial 2008 · n-3 PUFA group · Patients with chronic heart failure, New York Heart Association class II–IV | 1 g | 1424 days | 3,494 |
| Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT 2024 · icosapent ethyl group · Adults with established atherosclerotic cardiovascular disease and elevated triglycerides, receiving stable statin therapy | 4 g | 1752 days | 2,892 |
| Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico 1999 · n-3 PUFA · Patients who survived a recent myocardial infarction (within 3 months); age and sex not specified | 1 g | 1278 days | 2,836 |
| Identifying women who may benefit from higher dose omega-3 supplementation during pregnancy to reduce their risk of prematurity: exploratory analyses from the ORIP trial 2023 · n-3 arm · Pregnant women with singleton pregnancies; age range and condition other than pregnancy not specified | 900 mg | — | 2,654 |
| Predictors of compliance with higher dose omega-3 fatty acid supplementation during pregnancy and implications for the risk of prematurity: exploratory analysis of the ORIP randomised trial 2023 · intervention group · Pregnant women enrolled before 20 weeks’ gestation; analysis restricted to singleton pregnancies with known gestational age at birth | 900 mg | — | 2,654 |
| Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI 2022 · Icosapent ethyl · Adults with prior percutaneous coronary intervention, elevated triglycerides despite statin therapy, and established cardiovascular disease or diabetes with additional risk factors; at least 45 years old with established cardiovascular disease or at least 50 years old with diabetes | 4 g | 1752 days | 1,737 |
| Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States 2024 · icosapent ethyl (IPE) · Adults with elevated triglycerides and controlled LDL-C who had cardiovascular disease or diabetes plus additional cardiovascular risk factors; statin-stabilized | 4 g | 1789 days | 1,548 |